Coxibs Versus Combination NSAID and PPI Therapy for Chronic Pain: An Exploration of the Risks,Benefits,and Costs

Abstract

Spanish

French

Objective:

To systematically review studies qualitatively to compare the risks (gastrointestinal [Gl] and cardiovascular) and benefits (pain control) of cyclooxygenase-2 inhibitors (coxibs) relative to an alternative therapy of a nonselective nonsteroidal antiinflammatory drug (NSAID) combined with a proton-pump inhibitor (PPI) and explore circumstances when coxibs may be appropriate.

Methods:

Relevant studies were identified through a search of MEDLINE (Ovid Technologies, 1985–November 2005; English language, clinical trial), PubMed (1985–November 2005; English language, clinical trial, humans), and the Cochrane Collaboration using the terms selective COX-2 inhibitors and coxibs, as well as the various chemical names for specific coxib agents. Studies that compared a coxib with a nonselective NSAID and provided data concerning our outcomes of interest were included and categorized by the outcome variable, as well as by the specific coxib studied.

Results:

The majority of the numerous studies that evaluated pain as an endpoint showed no difference between coxib and nonselective NSAID therapy. However, while limited, preliminary safety data regarding the effects of both classes on the upper and lower Gl tract suggest coxib superiority. Although coxibs are associated with an increased risk of cardiovascular adverse events (CVEs) compared with placebo, this effect has not been conclusively shown compared with nonselective NSAIDs. Currently, coxib therapy is more expensive than combination therapy using a nonselective NSAID plus a PPI.

Conclusions:

Compared with combination therapy including a nonselective NSAID and PPI, coxibs provide equivalent pain control and may have a lower Gl tract complication profile, but at an unknown increased risk of CVEs and a greater financial cost. Coxib therapy may be an appropriate treatment for chronic pain in select patients with higher risks of Gl complications, lower risk of CVEs, and in whom greater cost is not a restraint.

Keywords

chronic pain nonsteroidal antiinflammatory drugs proton pump Inhibitors selective coxibs

Get full access to this article

View all access options for this article.

References

Finckh

, Aronson

. Cardiovascular risks of cyclooxygenase-2 inhibitors: where we stand now. Ann Intern Med 2005;142:212–4.

Drazen

. COX-2 inhibitors—a lesson in unexpected problems N Engl J Med 2005; 352: 1131–2.

Topol

. Arthritis medicines and cardiovascular events—“house of coxibs.” JAMA 2005; 293: 366–8.

BBC. Heart disease painkiller warning. BBC NEWS 2005; http://news.bbc.co.uk/go/pr/fr/-/w/hi/health/4276211.stm (accessed 2005 May 20).

Food and Drug Administration CfDEaR. COX-2 selective (includes Bextra, Celebrex, and Vioxx) and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). www.fda.gov/cder/drug/infopage/COX2/default.htm. April 6, 2005 (accessed 2005 May 22).

US Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med 2002;136:157–60.

Gaspoz

, Coxson

, Goldman

. Cost effectiveness of aspirin, Clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med 2002;346:1800–6.

Laine

Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001;120:594–606.

Hooper

, Brown

, Elliott

, Payne

, Roberts

, Symmons

The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ 2004;329:948–57.

10.

Psaty

, Furberg

. COX-2 inhibitors—lessons in drug safety. N Engl J Med 2005;352:1133–5.

11.

Chan

, Hung

, Suen

. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002;347:2104–10.

12.

Nussmeier

, Whelton

, Brown

. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005;352:1081–91.

13.

ADAPT. Alzheimer's Disease Anti-Inflammatory Prevention Trial. National Institutes of Health News, www.nih.gov/news/pr/dec2004/od-20.htm (accessed 2005 Mar 1).

14.

PreSAP. FDA Advisory Committee on COX-2 Inhibitors & NSAIDs, Gaithersburg, MD, February 16–18, 2005. PreSAP Study. www.fda.gov/ohrms/dockets/ac/05/slides/2005-4090S1_09_FDA-Levin_files/frame.htm (accessed 2005 Feb 28).

15.

Bensen

, Fiechtner

, McMillen

. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 1999;74:1095–105.

16.

Kivitz

, Moskowitz

, Woods

Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip. J Int Med Res 2001;29:467–79.

17.

McKenna

, Borenstein

, Wendt

, Wallemark

, Lefkowith

, Geis

. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand J Rheumatol 2001;30:11–8.

18.

Simon

, Weaver

, Graham

. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999;282:1921–8.

19.

Zhao

, McMillen

, Markenson

. Evaluation of the functional status aspects of health-related quality of life of patients with osteoarthritis treated with celecoxib. Pharmacotherapy 1999;19:1269–78.

20.

Battisti

, Katz

, Weaver

. Pain management in osteoarthritis: a focus on onset of efficacy—a comparison of rofecoxib, celecoxib, acetaminophen, and nabumetone across four clinical trials. J Pain 2004;5:511–20.

21.

Bombardier

, Laine

, Reicin

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520–8, 2 p following 8.

22.

Day

, Morrison

, Luza

A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/lbuprofen Comparator Study Group. Arch Intern Med 2000;160:1781–7.

23.

Kivitz

, Greenwald

, Cohen

. Efficacy and safety of rofecoxib 12.5 mg versus nabumetone 1,000 mg in patients with osteoarthritis of the knee: a randomized controlled trial. J Am Geriatr Soc 2004; 52:666–74.

24.

Myllykangas-Luosujarvi

, Lu

, Chen

. Comparison of low-dose rofecoxib versus 1000 mg naproxen in patients with osteoarthritis. Results of two randomized treatment trials of six weeks duration. Scand J Rheumatol 2002;31:337–44.

25.

Truitt

, Sperling

, Ettinger

Jr. A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis. Aging (Milano) 2001;13:112–21.

26.

Bensen

, Weaver

, Espinoza

Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: a randomized, controlled comparison with placebo and naproxen. Rheumatology (Oxford) 2002;41:1008–16.

27.

Kivitz

, Eisen

, Zhao

, Bevirt

, Recker

. Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis. J Fam Pract 2002;51:530–7.

28.

Makarowski

, Zhao

, Bevirt

, Recker

. Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen. Osteoarthritis Cartilage 2002;10:290–6.

29.

Pavelka

, Recker

, Verburg

. Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial. Rheumatology (Oxford) 2003;42:1207–15.

30.

Collantes

, Curtis

, Lee

. A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273], BMC Fam Pract 2002; 3: 1–10.

31.

Gottesdiener

, Schnitzer

, Fisher

Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis. Rheumatology (Oxford) 2002;41:1052–61.

32.

Leung

, Malmstrom

, Gallacher

. Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: a randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial. Curr Med Res Opin 2002;18:49–58.

33.

Matsumoto

, Melian

, Mandel

. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatol 2002;29:1623–30.

34.

Zacher

, Feldman

, Gerii

A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis. Curr Med Res Opin 2003;19:725–36.

35.

Schnitzer

, Beier

, Geusens

Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: a phase II, four-week, multicenter, randomized, doubleblind, placebo-controlled trial. Arthritis Rheum 2004;51:549–57.

36.

Chan

, Hung

, Suen

. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. Gastroenterology 2004;127:1038–43.

37.

Goldstein

, Eisen

, Lewis

, Gralnek

, Zlotnick

, Fort

. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005;3:133–41.

38.

Laine

, Connors

, Reicin

Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 2003;124:288–92.

39.

Silverstein

, Faich

, Goldstein

. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247–55.

40.

White

, Faich

, Whelton

Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 2002;89:425–30.

41.

Konstant

, Weir

, Reicin

Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001;104:2280–8.

42.

Weir

, Sperling

, Reicin

, Gertz

. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. Am Heart J 2003;146:591–604.

43.

White

, Faich

, Borer

, Makuch

. Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. Am J Cardiol 2003;92:411–8.

44.

White

, Strand

, Roberts

, Whelton

Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis. Am J Ther 2004;11:244–50.

45.

Mukherjee

, Nissen

, Topol

. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954–9.

46.

Juni

, Nartey

, Reichenbach

, Sterchi

, Dieppe

, Egger

Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004;364:2021–9.

47.

Ray

, Stein

, Daugherty

, Hall

, Arbogast

, Griffin

. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002;360:1071–3.

48.

Mamdani

, Juurlink

, Lee

. Cyclooxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004;363:1751–6.

49.

Solomon

, Karlson

, Rimm

. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003;107:1303–7.

50.

Graham

, Campen

, Hui

Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case–control study. Lancet 2005;365:475–81.

51.

Kimmel

, Berlin

, Reilly

Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 2005;142:157–64.

52.

Farkouh

, Kirshner

, Harrington

. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004;364:675–84.

53.

Thun

, Henley

, Patrono

Nonsteroidal anti-inflammatory drags as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002;94:252–66.

54.

Bresalier

, Sandler

, Quan

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092–102.

55.

Solomon

, McMurray

, Pfeffer

. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071–80.

56.

2004 Red book. Montvale, NJ: Thomson PDR, 2004.

57.

MacDonald

, Wei

Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003;361:573–4.

58.

Garcia Rodriguez

, Varas

, Patrono

Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology 2000;11:382–7.

59.

Garcia Rodriguez

, Varas-Lorenzo

, Maguire

, Gonzalez-Perez

Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. Circulation 2004;109:3000–6.

60.

Macari

, Bini

, Xue

Colorectal neoplasms: prospective comparison of thin-section low-dose multi-detector row CT colonography and conventional colonoscopy for detection. Radiology 2002;224:383–92.

61.

Mamdani

, Rochon

, Juurlink

. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocanlial infarction in the elderly. Arch Intern Med 2003;163:481–6.

62.

Alexandrou

, Davis

, Law

, Murthy

, Whooley

, Wong

Squamous cell carcinoma and adenocarcinoma of the lower third of the esophagus and gastric cardia: similarities and differences. Dis Esophagus 2002;15:290–5.

63.

Solomon

, Glynn

, Levin

, Avom

Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med 2002; 162:1099–104.

64.

Rahme

, Pilote

, LeLorier

Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med 2002; 162:1111–5.

65.

Watson

, Rhodes

, Cai

, Guess

. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med 2002;162:1105–10.

66.

Cryer

COX-2-specific inhibitor or proton pump inhibitor plus traditional NSAID: is either approach sufficient for patients at highest risk of NSAID-induced ulcers?

Gastroenterology 2004;127:1256–8.